Advanced lytic lesion is a poor mobilization factor in peripheral blood stem cell collection in patients with multiple myeloma.
Jung SH et al. J Clin Apher. 2014 Apr 25. doi: 10.1002/jca.21326. [Epub ahead of print].
Clinical features, outcome and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the greek myeloma study group in 97 patients.
Katodritou E et al. Am J Hematol. 2014 Apr 23. doi: 10.1002/ajh.23745. [Epub ahead of print].
Can genome array screening replace FISH as a front-line test in multiple myeloma?
Boneva T et al. Genes Chromosomes Cancer. 2014 Apr 23. doi: 10.1002/gcc.22178. [Epub ahead of print].
Utilization of Magnetic-Activated Cell Sorting and High-Density Single Nucleotide Polymorphism Microarrays Improves Diagnostic Yield and Prognostic Value in Clinical Testing for Patients with Multiple Myeloma and Normal Routine Chromosome Study.
Christensen T et al. Acta Haematol. 2014 Apr 17;132(2):233-236. [Epub ahead of print].
Urinary investigations in the diagnosis and monitoring of monoclonal gammopathies in daily practice.
Oudart JB et al. Ann Biol Clin (Paris). 2014 Apr 1;72(2):147-152.
Serum free light chain evaluation as a marker for the impact of intra-clonal heterogeneity on the progression and treatment resistance in multiple myeloma.
Brioli A et al. Blood. 2014 Apr 14. [Epub ahead of print].
Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.
Amin SB et al. Leukemia. 2014 Apr 15. doi: 10.1038/leu.2014.140. [Epub ahead of print].
Circulating levels of soluble Fas ligand reflect disease progression in multiple myeloma.
Alexandrakis MG et al. Med Oncol. 2014 May;31(5):953. doi: 10.1007/s12032-014-0953-0. Epub 2014 Apr 13.
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.
Chretien ML et al. Haematologica. 2014 Apr 11. [Epub ahead of print].
Quantification of peptides from immunoglobulin constant and variable regions by liquid chromatography-multiple reaction monitoring mass spectrometry for assessment of multiple myeloma patients.
Remily-Wood ER et al. Proteomics Clin Appl. 2014 Apr 10. doi: 10.1002/prca.201300077. [Epub ahead of print].
Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients.
Rampa C et al. Biomark Res. 2014 Apr 9;2(1):8. doi: 10.1186/2050-7771-2-8.
Impact of initial FGD-PET CT and Serum Free Light Chain on transformation of conventionally defined Solitary Plasmacytoma to Multiple Myeloma.
Fouquet G et al. Clin Cancer Res. 2014 Apr 8. [Epub ahead of print].
Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK et al. Int J Cancer. 2014 Apr 7. doi: 10.1002/ijc.28877. [Epub ahead of print].
MYC Protein Expression Is Detected in Plasma Cell Myeloma but Not in Monoclonal Gammopathy of Undetermined Significance (MGUS).
Xiao R et al. Am J Surg Pathol. 2014 Apr 3. [Epub ahead of print].
The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma.
Caers J et al. Haematologica. 2014 Apr;99(4):629-37. doi: 10.3324/haematol.2013.091918.
11C-Acetate PET/CT for Metabolic Characterization of Multiple Myeloma: A Comparative Study with 18F-FDG PET/CT.
Ho CL et al. J Nucl Med. 2014 Mar 27. [Epub ahead of print].
The imaging prevalence of osteolytic metastasis or multiple myeloma presenting as a periprosthetic lucency in the hip.
Schneider E et al. AJR Am J Roentgenol. 2014 Apr;202(4):811-8. doi: 10.2214/AJR.12.10510.
MRI features of extramedullary myeloma.
Tirumani SH et al. AJR Am J Roentgenol. 2014 Apr;202(4):803-10. doi: 10.2214/AJR.13.10856